@QuickDraw - Very nice job. I sincerely appreciate your

New Post Public Reply Private Reply Replies (3) Message Board
Bsav88atty tryz #3265
@QuickDraw - Very nice job. I sincerely appreciate your efforts.

There were numnerous good points raised during the interview that are worth repeating:

First, I must admit that I was wrong about the convertible debt debate. Of course, I was not the only one with an incorrect opinion on this subject, and it appears my "unfriendly" v. "friendly" opinion was more correct. Bob clearly stated that no new toxic debt has been written since his birthday, October 22, 2013. Bob clarified the Q1 report disclsoure. Specifically, the "additional convertible debt" disclosed in the Q1 report was merely the renewed and extended debt held by three individuals, two of his closests friends and his wife! So for all the venom directed at Bob on his alleged broken promise, you have once again been proved wrong.

I enjoyed hearing how he plans to develop SCRC's interest in WholesaleRx and PIMD to become a mini-McKesson (Bob's words, by the way). It is clear to me that this part of the business will grow and become what I have been expecting, though it is taking a bit longer than anticipated.

Bob is still psyched about RapiMeds, especially the China opportunity. And after RapiMeds "gets going", he believes it and the specialty pharmacy business (a/k/a the "crown jewel" at the moment) will "go neck-and-neck". Frankly, from the tone of Bob's voice as he discussed the RapiMeds opportunity in China due to that market's need for U.S.-made products, the focused concern for children in China, and the new RapiMed product in development, I have a hunch that Bob still believes that RapiMeds revenues will eventually become the company's new crown jewel. But this is just my opinion, and the specialty pharmacy business clearly has an enormous lead at this time.

Bob reported there is no capacity limitataions with the current RapiMeds manufacturer, which currently manufactures products for the worlds largests pharmacy retailers. He also structured a profitable financial model in which the company is paid within 30 days of product delivery to the distributor, which eliminates unrecoverable payables issues and increases the profit margins, as the distributors and retailers are solely responsible for all marketing and selling expenses in their respective markets. Hopefully, our distributors can generate a strong interest and demand for RapiMed products and, thus, significantly increase orders and sales of RapiMeds there.

On to the specialty pharmacy business, which Bob described as the "crown jewel". In response to QuickDraw's question about whether the recently reported revenues of $1.6 million are sustainable, Bob said, "it is just getting started." He said the company is adding more staff to handle what I believe to be even more Rx orders and, equally important, that the company is working on compounding pharmacy opportunities outside the sphere of Main Ave Pharmacy. So it appears that the crown jewel of SCRC will be adding many more crowns in the months ahead. And similar to the RapiMeds financial model, the specialty pharmacy business is also set up on a 30-day payment period and they have no collections problems.

Bob said he would be happy to do a follow up interview in a few months, "hopefully, things will be double what they are now."

Bob also addressed a question about the PIPE deal, and explained that his SEC counsel advised him that an 8K was not warranted because these were seperate private deals, each of which did not amount to a material amount that required an 8K. Regardless, the PIPE deals were disclosed in the 10K and again in the 10Q. Bob also added that the shares issued in exhcange for the financing obtained in private subscription agreements were restricted, which was not disclosed in the financial reports. He said the money obtained from these deals was from solid investors (e.g. friends and family), with whom the company has a good relationship, implying that these shares will not be dumped on the market as soon as they unlock (contrary to opinions expressed on this board on numerous occassions).

Bob said Scrips "probably has the most loyal shareholders," and that he welcomes calls from people interested in investing in SCRC. If he can answer a caller's question he will, if he cannot, he will openly say so. I enjoyed hearing his invitation to the listeners who are watching the company and still sitting on the fence: "Come on board and enjoy the ride!" His goal is to make the shareholders happy, which will require earning more revenues, making a profit, and ultimately growing the share price. As a longterm shareholder, I look forward to enjoying the ride.

ScripsAmerica Inc (SCRC) Stock Research Links

SCRC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 39

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 25

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 75

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 32

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 23

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 17

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon.com Options Insights: Market Sentiment Shifts in Focus

Updated Category News Views 299

Amazon.com Options Insights: Market Sentiment Shifts in Focus Investors are showing a notable optimistic stance towards Amazon.com (NASDAQ: AMZN), and ignoring this momentum would be unwise. Recent insights into options trading reveal significant movements that could signal important changes ahead. Our analysis of options data indicates that a substantial number of trades...

Continue Reading
Global Job Vacancies Decline Amid Economic Uncertainty

Updated Category News Views 278

Global Job Vacancies Experience a Notable Decrease LONDON - A recent survey highlights a decline in white-collar job vacancies worldwide, attributed to various factors such as the U.S. election, uncertainty around tax increases in the U.K., and escalating geopolitical tensions. Insights from the Recruitment Sector The monthly Global Jobs Index released by recruitment...

Continue Reading
Jura Energy Corporation Releases Interim Financial Statements

Updated Category News Views 194

Jura Energy Corporation Announces Interim Filings Release Jura Energy Corporation has announced the filing of its condensed consolidated interim financial statements as of June 30, 2024. This report details the company's financial performance for the three and six months leading up to this date. The information is available on SEDAR, along with the Management’s...

Continue Reading
Understanding the Recent Short Interest Trends for Sun Communities

Updated Category News Views 127

Analyzing Sun Communities' Short Interest Dynamics Sun Communities (NYSE: SUI) recently reported a notable change in its short interest percentage, which has seen a decrease of 5.23% since the latest report. The data indicates that currently, there are 1.38 million shares sold short, representing 1.45% of the company’s publicly available shares for trading. This...

Continue Reading
Concentric Energy Advisors Expands Team with Industry Expert

Updated Category News Views 296

Concentric Energy Advisors Welcomes New Expertise Concentric Energy Advisors, Inc. is excited to announce a significant addition to its team. The firm proudly introduces Ms. Christine Saball as the new Assistant Vice President. Recognized for her extensive background in management consulting services for the North American energy sector, Ms. Saball brings over twenty...

Continue Reading